ImClone, Sanofi-Aventis Settle Erbitux Patent Dispute
This article was originally published in The Pink Sheet Daily
Executive Summary
Each company will pay Israel’s Yeda $60 million, but ImClone also gains license for a patent critical to the production of cetuximab.